Healthcare Professionals

Committed to helping you meet the evolving challenges and opportunities in patient care.

Healthcare Professionals
  • Primary Care

    Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

  • Hospital Care

    Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

  • Surgical Care

    Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

  • Kidney Care

    Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

  • Nutritional Care

    Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

  • Respiratory Care

    Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

  • Our Products

    Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspectives

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Perspectives

Our Story

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Leadership

    Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fueling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • Corporate Responsibility

    We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

  • Diversity, Equity & Inclusion

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

  • Our History

    For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Patients

Helping you reach a healthy life, full of possibility.

Patients
  • General Healthcare

    Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

  • Nutritional Care

    When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

  • Kidney Care

    Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

  • Respiratory Care

    We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

Baxter Receives Grant From German Federal Ministry of Education and Research to Lead Extracorporeal Blood Purification Research

Press Release

  • Focused on enabling more selective approaches for certain extracorporeal blood purification (EBP) therapies

  • Led by Baxter’s renowned research and development team in Hechingen, Germany

PDF

DEERFIELD, Ill. -

Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced it received a new research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF). With the grant, Baxter will lead an initiative aiming to create a new technology platform enhancing the ability to target selective removal of pathogenic substances during certain extracorporeal (outside the body) blood purification (EBP) therapies. The grant provides €1.5 million in funding over three years to Baxter and its research partners through the BMBF’s “Biomaterials Platform: Mat2MedTech” program. 

EBP therapies are used in patients with a variety of acute and chronic diseases, including acute kidney injury (AKI), autoimmune diseases, sepsis and liver failure. During certain EBP therapies, the patient’s blood travels through an extracorporeal device, where pathogenic substances are cleared by attaching to an adsorbent biomaterial before the blood is returned to the patient’s body. The hemocompatibility of the biomaterial’s surface is critical to enabling its biological function without harming blood cells or causing coagulation. There is currently a focus on developing and enhancing biomaterials that mimic human tissue properties to selectively target pathogenic substances for removal, while preserving essential blood components such as albumin, immunoglobulins, clotting factors and blood cells.

Baxter and its research partners, including Rapp Polymere GmbH in Tuebingen, Germany, will help advance these efforts by identifying and analyzing potential modifications of biomaterials and hemocompatible coatings. This will potentially support creation of a technology platform enabling more targeted removal of selective molecules, proteins and cellular elements during certain EBP therapies, while preventing sequestration of coagulative factors, platelet depletion and hemolysis. Rapp Polymere GmbH will lend its expertise in biomaterials and coating to the initiative. 

“As a leader in multi-organ support therapies, we are relentless in our efforts to continuously advance research that helps meet the needs of critically ill patients around the world,” said Kadri Jabri, vice president, R&D, Acute Therapies at Baxter. “We are proud that our research and development team in Hechingen will play such a major role in this collaborative effort to introduce new technology for EBP therapies.”  

Baxter has received two previous research grants from the BMBF. These include a 2019 grant through BMBF’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis option for end-stage renal disease (ESRD) patients and a 2012 grant through BMBF’s “BioMatVital: BioDisposables” project to investigate a new generation of dialysis membranes to improve the treatment of chronic inflammation in ESRD patients.

About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release includes forward-looking statements based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter is a registered trademark of Baxter International Inc.